INNOVENT BIO(01801),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community - To The Moon

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

01801 INNOVENT BIO

Not Yet Opened 10-07 16:08:52

97.500

-1.850

-1.86%

High98.950	Low96.250	Vol4.42M
Open97.000	D1 Closing99.350	Amplitude2.72%
Mkt Cap170.14B	Tradable Cap170.14B	Total Shares1.75B
T/O429.56M	T/O Rate0.25%	Tradable Shares1.75B
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

Disclaimer: HKEx Information Services Limited, its holding companies and/or any subsidiaries of such holding companies endeavour to ensure the accuracy and reliability of the information provided, but do not guarantee its absolute accuracy and reliability and accept no liability (whether in tort or contract or otherwise) for any loss or damage arising from any inaccuracies or omissions.

{"stockData":{"symbol":"01801","market":"HK","secType":"STK","nameCN":"INNOVENT BIO","latestPrice":97.5,"timestamp":1791360532004,"preClose":99.35,"halted":0,"volume":4416662,"delay":0,"changeRate":-0.01862103673880216,"floatShares":1745000000,"shares":1745000000,"eps":0.469999,"marketStatus":"Not Yet Opened","change":-1.85,"latestTime":"10-07 16:08:52","open":97,"high":98.95,"low":96.25,"amount":429561000,"amplitude":0.027177,"askPrice":97.5,"askSize":18500,"bidPrice":97.4,"bidSize":4500,"shortable":3,"etf":0,"ttmEps":0.803379,"tradingStatus":0,"nextMarketStatus":{"tag":"Open","tradingStatus":2,"beginTime":1791423000000},"marketStatusCode":0,"adr":0,"listingDate":1540915200000,"exchange":"SEHK","adjPreClose":99.35,"openAndCloseTimeList":[[1791336600000,1791345600000],[1791349200000,1791360000000]],"volumeRatio":0.459512,"lotSize":500,"spreadScale":0,"tradeCurrency":"HKD","optionSymbol":"INB.HK","impliedVol":0.4828,"impliedVolPercentile":0.4837},"requestUrl":"/m/hq/s/01801/wiki","defaultTab":"wiki","newsList":[{"id":"2673162410","title":"Is Innovent Biologics (SEHK:1801) Undervalued After Jaypirca Approval And New IBI3003 Data?","url":"https://stock-news.laohu8.com/highlight/detail?id=2673162410","media":"Simply Wall St.","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2673162410?lang=en_us&edition=fundamental","pubTime":"2026-10-07 18:28","pubTimestamp":1791368938,"startTime":"0","endTime":"0","summary":"Innovent Biologics (SEHK:1801) is back in focus after two cancer drug updates. China’s NMPA cleared Jaypirca for broader CLL/SLL use, and new Phase 1 data for IBI3003 in multiple myeloma drew attention.\nThese twin drug updates hit a market that has already been warming to Innovent Biologics, with the share price at HK$97.5 after a 90-day share price return of 12.91% and a three-year total shareholder return of 127.27%, even though the one-year total shareholder return is down...","market":"hk","thumbnail":"https://simplywall.st/cdn-cgi/image/fit=cover,format=auto,width=320,height=180/https://images.simplywall.st/asset/industry/6111000-choice1-card/1788937617532","type":0,"news_type":0,"thumbnails":["https://simplywall.st/cdn-cgi/image/fit=cover,format=auto,width=320,height=180/https://images.simplywall.st/asset/industry/6111000-choice1-card/1788937617532"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/hk/pharmaceuticals-biotech/hkg-1801/innovent-biologics-shares/news/is-innovent-biologics-sehk1801-undervalued-after-jaypirca-ap","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/hk/pharmaceuticals-biotech/hkg-1801/innovent-biologics-shares/news/is-innovent-biologics-sehk1801-undervalued-after-jaypirca-ap","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["DCF","LU0455707207.USD","LU1188198961.HKD","LU2097828474.EUR","BK1161","KURE","01801","LU0244354667.USD","LU2097828631.EUR","LU2097828714.EUR","LU0607220059.USD","LU2242644610.SGD","BK1589","BK1583","LU0502904849.HKD","LU1831875114.USD","LU2328871848.SGD","LU2097828805.USD","LU0326950275.SGD","LU1969619763.USD","LU0463099449.HKD","HK0000165453.HKD","LU0149534421.HKD","LU2097828557.USD","LU2488822045.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1100401576","title":"Movement Alert｜INNOVENT BIO Falls 3.07% in Regular Trading, Biotech Sector Under Pressure","url":"https://stock-news.laohu8.com/highlight/detail?id=1100401576","media":"Market Focus","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1100401576?lang=en_us&edition=fundamental","pubTime":"2026-10-07 10:13","pubTimestamp":1791339226,"startTime":"0","endTime":"0","summary":"On October 7, INNOVENT BIO fell 3.07% in regular trading, trading at 96.3 Hong Kong dollars per share, with turnover of 160 million Hong Kong dollars.Within the Biotechnology sector where INNOVENT...","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01801"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2672715686","title":"Major Drugmakers Turn to China for Licensing Deals","url":"https://stock-news.laohu8.com/highlight/detail?id=2672715686","media":"Reuters","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2672715686?lang=en_us&edition=fundamental","pubTime":"2026-10-02 17:50","pubTimestamp":1790934645,"startTime":"0","endTime":"0","summary":"FACTBOX-Major drugmakers turn to China for licensing dealsOct 2 (Reuters)-Abogen said on Friday it has signed a licensing deal worth up to $7.8 billion with Swiss drugmaker NovartisNOVN.Sto develop an","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20261002:nL4N45O0HV:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK0183","LU2476274720.SGD","LU0225771236.USD","LU2646069778.SGD","LU2023250843.SGD","IE00B7KXQ091.USD","LU1236620750.USD","LU0708994859.HKD","LU2461242641.AUD","LU0306807586.USD","LU1244550221.USD","LU1226287792.SGD","LU0198837287.USD","LU1670627923.USD","LU0079474960.USD","LU2133065610.SGD","LU1831875114.USD","LU2355687059.USD","LU0672654240.SGD","LU2539964713.USD","LU0171293334.USD","LU0526926950.USD","LU2213496289.HKD","LU2242644610.SGD","IE000WAW04H5.SGD","LU1084165304.USD","IE00B19Z3581.USD","SG9999001176.SGD","IE00BKPKM643.USD","LU0256863902.USD","LU1670710588.SGD","LU1127390331.HKD","LU1153584641.USD","LU1670710661.SGD","LU2023251221.USD","PJP","BK4535","LU1720051017.SGD","LU0787776722.HKD","LU0997586432.USD","LU1066051498.USD","LU0792757196.USD","HK0000165453.HKD","LU1400636574.HKD","LU2106854487.HKD","LU1868836914.USD","LU1116320901.HKD","LU2495084118.USD","LU0310799852.SGD","LU0158827948.USD","LU2129689431.USD","LU2476274308.USD","LU0575583348.USD","THNR","LU0320765992.SGD","LU2552382132.HKD","LU0047473722.EUR","LLYZ","BMY","LU2168564495.EUR","LU0109981661.USD","LU2462591350.SGD","HCM","IBB","BK0060","IE000M9KFDE8.USD","IE00B1XK9C88.USD","LU0965509010.AUD","LU0265550946.USD","LU0965509101.SGD","LU1261432733.SGD","LU0244354667.USD","BK5011","IE00B031HY20.USD","LU0971552673.USD","LU1481599808.USD","LU0094547139.USD","LU0029864427.USD","LU0912757837.SGD","SG9999015341.SGD","LU0211326755.USD","LU1064131003.USD","LU2237443978.SGD","SG9999015986.USD","LU2289578879.USD","LU1226288170.HKD","BK4581","LU0069063385.USD","LU1244550494.USD","LU1989772840.SGD","LU0972486137.USD","SG9999011175.SGD","IE00B19Z3B42.SGD","LU0920840948.USD","GLAM","LU0314109678.HKD","LU1023059063.AUD","LU0971552830.HKD","LU0784384876.USD","ABBV","LU0889565916.HKD","LU2111349929.HKD","LLYX","IE00BZ08YS42.EUR","LU0061475181.USD","BK1588","LU1037948897.HKD","LU1019634622.SGD","LU0238689110.USD","NVOX","LU0689626769.HKD","LU1883839398.USD","LU2129689605.HKD","600276","LU0306806265.USD","LU2114397693.USD","LU2746668461.USD","LU0965508806.USD","LU0963555726.SGD","LU0097036916.USD","LU0395794307.EUR","LU1280957306.USD","LU1255011170.USD","IE00BQJZX424.USD","LU0006306889.USD","LU0310800965.SGD","LU0857590862.USD","LU1929549753.HKD","LLY","LU1066053197.SGD","LU0634319403.HKD","LU1997245094.SGD","LU1226287875.USD","LU1273509221.SGD","NVO","LU0154236417.USD","LU1003076772.USD","LU0980610538.SGD","SMMT","LU0463099449.HKD","SG9999015978.USD","LU0882574055.USD","LU1032466523.USD","LU0353189680.USD","LU0234570918.USD","LU2433249047.HKD","LU2211815571.USD","GDOC","LU2028103732.USD","LU2129689514.USD","IE00BN29S564.USD","LU1201861249.SGD","LU1629891620.HKD","LU0640478417.SGD","BK4585","LU0348825331.USD","LU1670756490.USD","LU2324357040.USD","LU2491049909.HKD","SG9999001440.SGD","LU1732800096.USD","LU2488822045.USD","LU0211328371.USD","BK1583","LU1699723380.USD","LU1670711123.USD","BK1191","BK1161","BK4533","LU2417539215.USD","LU1061106388.HKD","IE00B5MMRT66.SGD","IE00BKDWB100.SGD","LU0070302665.USD","LU1894683264.USD","LU0315179316.USD","LU0957799991.USD","LU1496350171.SGD","LU2362541513.USD","LU1863844749.USD","LU0158827781.USD","SG9999014559.SGD","BK4139","LU1934455277.USD","LU0823399737.USD","LU1989771016.USD","LU0949170426.SGD","MHIP","LU2125154778.USD","BK4534","LU1839511570.USD","LU0072461881.USD","LU0321505868.SGD","LU0385154629.USD","LU1226287529.USD","LU1226288253.USD","03165","LU1807302812.USD","IE0004445015.USD","LU2237438978.USD","LU2264538146.SGD","LU1820825898.SGD","LU1988902786.USD","BK4516","LU0823416689.USD","LU1035777561.USD","LU2580892862.HKD","LU2237443895.HKD","LU0784383803.USD","LU0640476718.USD","IE00BJJMRZ35.SGD","LU0234572021.USD","NVOH","LU2148510915.USD","IE0034235071.USD","LU0096364046.USD","LU0868494617.USD","LU0162691827.USD","LU0960981461.USD","LU1720051108.HKD","ELIL","IE00B3M56506.USD","LU1228905037.USD","LU2293690249.USD","LU0985320562.USD","NVS","LU0345770993.USD","LU1267930730.SGD","LU1037948541.HKD","LU0997586515.USD","CANC","IE0001KFT4U8.USD","IE00BLSP4239.USD","LU0471298777.SGD","LU1232071149.USD","01801","TRUH","LU0098860793.USD","MEDI","IE00BFTCPJ56.SGD","IE00B543WZ88.USD","SG9999003800.SGD","LU1997245177.USD","LU0432979614.USD","VHT","IE00BFSS7M15.SGD","LU0417516571.SGD","LU1941712348.USD","IHE","LU2236285917.USD","LU0077335932.USD","LU1960683339.HKD","LU1585245621.USD","IE00BWDBJ516.SGD","02096","LU0861579265.USD","LU0067412154.USD","LU0174119429.USD","LU1997244956.HKD","LU0122379950.USD","LU0267386448.USD","PAWZ","BK4551","LU1035773651.USD","LU1804176565.USD","IE000MB6IJN5.SGD","LU2168564222.USD","BK1574","LU0057025933.USD","LU2293690082.USD","IE00BSNM7G36.USD","IE00BDGV0183.EUR","LU1267930573.SGD","LU2471134952.CNY","LU0348784397.USD","IE000F7OJYX1.SGD","LU2602419157.SGD","IE00BKPKM429.USD","LU0203201768.USD","MRK","LU0456855351.SGD","TMED","LU2750360641.GBP","LU0784385170.HKD","LU0128525689.USD","SGXZ99366536.SGD","LU1983299246.USD","LU0417516738.SGD","LU0320765059.SGD","IE000SO60NU8.SGD","LU0326950275.SGD","IE00BFXG1179.USD","LU0795875169.SGD","PFE","SG9999014542.SGD","LU0011850046.USD","LU0225284248.USD","LU0502904849.HKD","ILDR","SG9999018865.SGD","LU0880133367.SGD","LU0211327993.USD","LU0477156953.USD","LU0920783379.SGD","IE0034235188.USD","LU2462157665.USD","03692","IE00BJJMRY28.SGD","LU0868494708.USD","LU1069347547.HKD","LU0708995401.HKD","SG9999014906.USD","LU0943347566.SGD","LU2456880835.USD","BK1587","LU2112291526.USD","LU1941712264.USD","IE00BZ08YR35.GBP","IE00B4JS1V06.HKD","LU1951186391.HKD","LU1267930227.SGD","LU0047473722.SGD","LU1868837136.USD","LU0472753341.HKD","LU2089283258.USD","LU0256863811.USD","LU0405327494.USD","LU0511384066.AUD","LU2552382058.USD","OZEM","LU2168563687.JPY","BMED","IYH","LU1487256676.USD","LU0320765489.SGD","LU2471134796.USD","IE00BVYPNV92.GBP","LU2362540622.SGD","LU2362541273.HKD","LU0820561818.USD","LU1116320737.USD","BK4007","LU0417516902.SGD","LU2471134523.USD","IE00BGHQF631.EUR","PPH","LU1064130708.USD","LU2746668974.SGD","LU0607220059.USD","LU2125909247.SGD","IE0008368742.USD","LU1917777945.USD","LU0052756011.USD","LU0496365809.HKD","LU0561508036.HKD","688506","LU1989772923.USD","LU2756315664.SGD","IE0008369823.USD","IE00BN8TJ469.HKD","LU0965509283.SGD","LU1046234339.USD","IE00BK4W5M84.HKD","LU2089284900.SGD","LU0540923850.HKD","LU2491050154.USD","LU0545562505.USD","LU0320765646.SGD","IE00BBT3K403.USD","LU0348766576.USD","LU0390134368.USD","LU1548497426.USD","09926","LU0648001328.SGD","IE00BJLML261.HKD","LU1145028129.USD","LU0265550359.USD","LU1481600234.SGD","LU1979441026.SGD","LU1051770623.HKD","LU2087621335.USD","IE00B775H168.HKD","LU0348735423.USD","LU1814569148.SGD","IE00BWXC8680.SGD","LU2271345857.HKD","00013","SGXZ57979304.SGD","LU2491050071.SGD","ELIS","LU0266013472.USD","LU1328277881.USD","LU2778985437.USD","IE000BZT7R73.USD","LU0661504455.SGD","LU1046248800.SGD","LU0106261372.USD","LU1152091754.HKD","LU2125909593.SGD","FHLC","LU1066051225.USD","01530","LU2242652126.USD","LU1323610961.USD","GB00BDT5M118.USD","LU0969580561.USD","LU0161305163.EUR","LU1880407215.USD","09995","LU2357305700.SGD","LU0072913022.USD","RHHBY","SGXZ51526630.SGD","LU1781817850.SGD","LU1196032939.SGD","03933","IE00BJJMRX11.SGD","BK4550","LU1170363599.USD","LU1069344957.HKD","LU1868837300.USD","SG9999017495.SGD","LU2328871848.SGD","LU1309081286.SGD","LU1732799900.SGD","IBBQ","LU1057294990.SGD","IE0002270589.USD","LU1066051811.HKD","LU0203345920.USD","LU0345770308.USD","LU0354030438.USD","SG9999001176.USD","LU0124676726.USD","LU0348783233.USD","LU1104425308.USD","LU1152091168.USD","LU1236620834.HKD","LU2237443465.HKD","LLII","LU0823434740.USD","LU0316494557.USD","LU0348827113.USD","IE0009355771.USD","LU2097828714.EUR","LU1302929846.USD","LU2023250504.SGD","LU2125154935.USD","LU2265009873.SGD","IE00BLSP4452.SGD","LU0208291251.USD","LU0471298694.HKD","LU0757432116.USD","BK0028","SG9999014575.USD","BK0188","LU1267930490.SGD","LU1655091616.SGD","01093","LU2360032135.SGD","KURE","LU0289739699.SGD","LU1098665638.USD","IXJ","LU2279689827.SGD","LU2237443622.USD","LU1993786604.SGD","LU1328615791.USD","IE00BJT1NW94.SGD","LU0354030511.USD","LU1301847155.USD","BK4532","LU0289739343.SGD","LU2361045086.USD","SG9999014567.USD","LU1670711040.USD","01276","LU1868836757.USD","LU1015430645.USD","LU1551013342.USD","IE00BZ08YT58.USD","LU0795875086.SGD","LU0323591593.USD","LU2552382215.SGD","LU1078025761.USD","BK1593","RXL","LU0203202063.USD","LU0726765562.USD","LU0133085943.USD","LU0964807845.USD","LU0738911758.USD","IE0002141913.USD","LU1228905540.USD","LU0058720904.USD","LU1691799644.USD","BK1521","SG9999014880.SGD","BK4559","SG9999015952.SGD","LU1064131342.USD","BK4592","SG9999002224.SGD","LU1645745479.HKD","IE00B42XCP33.USD","BK1589","LU1670628061.USD","LU1580142542.USD","LU0114720955.EUR","LU0820562030.AUD","LU0942090050.USD","LU1019632923.USD","LU0345777659.USD","IE00BVYPNW00.USD","AGNG","IE00B1BXHZ80.USD","LU1496350502.SGD","IE0005OL40V9.USD","LU1093756168.USD","SGXZ31699556.SGD","LU0887340254.USD","BK0012","LU1974910355.USD","NVOC","LU1267930813.SGD","LU1119994496.HKD","SG9999013999.USD","LU2168564149.EUR","LU1961090484.USD","TBXU","LU0348767384.USD","IE0004445239.USD","LU0557290698.USD","LU1003077747.HKD","LU0889566641.SGD","BK0196","LU1868836591.USD","LU0553294199.USD","LU0109394709.USD","LU1153585028.USD","LU2039709279.SGD","LU0211326839.USD","AZN.UK","IE00BZ1G4Q59.USD","LU2357627491.SGD","BK4568","SG9999014898.SGD","LU2168564065.EUR","SG9999002232.USD","LU0149534421.HKD","LU1355424745.HKD","LU0130102774.USD","IE00B4R5TH58.HKD","LU0203347892.USD","LU1162221912.USD","WDNA","LU0310800379.SGD","LU0455707207.USD","LU0171276677.USD","LU1571399168.USD","LU1934455194.USD","LU2750360997.AUD","LU0345777147.USD","LU2237443382.USD","BK4578","LU0784385840.USD","LU1244550577.SGD","LU2097828631.EUR","LU0321505439.SGD","LU0859254822.USD","LU2347655073.USD","LU0499090636.EUR","LU0964806797.USD","LU1188198961.HKD","LU0289961442.SGD","LU2063271972.USD","LU2242646821.SGD","LU0501845795.SGD","LU0545039389.USD","LU0689472784.USD","BNTX","LU2087625088.SGD","LU1366192091.USD","LU2097828805.USD","BK4588","IE00B3T34201.USD","LU1718418525.SGD","SG9999018857.SGD","LU0237698245.USD","LU0985481810.HKD","SG9999014914.USD","IE00BPRC5H50.USD","BK1515","JDOC","BK4566","IE00B2B36J28.USD","LU1863844665.USD","LU2468319806.SGD","LU1880407132.USD","LU3187612489.SGD","REGN","LU0820561909.HKD","LU1551013425.SGD","LU1202635105.USD","LU1720050803.USD","LU1969619763.USD","LU1291159041.SGD","LU1923622614.USD","LU2361044865.SGD","LU1829250122.USD","LU2097828557.USD","LU2237443549.SGD","LU0976567544.SGD","BK0239","HRTS","LU2089984988.USD","LU2399975544.HKD","LU0053666078.USD","BK4548","SG9999004220.SGD","688331","LU1813983027.USD","LU0211331839.USD","LU0170899867.USD","LU1035775433.USD","XLV","LU0417517546.SGD","LU0140636845.USD","LU0882574139.USD","LU0128525929.USD","LU2580892789.USD","LU2596442595.SGD","LU1623119135.USD","LU1794554557.SGD","BBH","LU0405327148.USD","LU2091194634.USD","LU1074936037.SGD","LU1093756325.SGD","LU2097828474.EUR","LU1400636657.SGD","LU0683600562.USD","LU0889565080.SGD","LU0786609619.USD","LU0109391861.USD","LU0353189763.USD","LU1064927863.SGD","FTXH","IE0000B7K699.USD","LU2360106947.USD","LU1400636491.USD","LU0210536198.USD","LU0130517989.USD","LU0225283273.USD","LU0827474353.SGD","LU0987226296.USD","SG9999015358.SGD","LU0466842654.USD","LU2347655156.SGD","IE00BFSS8Q28.SGD","MEDX","LU2023250330.USD","LU0823434583.USD","LU0949170772.SGD","LU2756315318.SGD","LU1934455863.HKD","LU2896262040.SGD","CURE","LU2361044949.HKD","LU2108987350.USD","LU2471134879.HKD","SGXZ81514606.USD","IE00B3PB1722.GBP","BK4599","IE00BKVL7J92.USD","LU1008478684.HKD","SG9999015945.SGD","GSK.UK","LU1712237335.SGD","LU1430594728.SGD","LU1894683348.USD","IE00BK4W5L77.USD","LU1146622755.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1147917794","title":"Movement Alert｜INNOVENT BIO Falls 3.47% in Regular Trading, Trading at HK$92.9","url":"https://stock-news.laohu8.com/highlight/detail?id=1147917794","media":"Market Focus","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1147917794?lang=en_us&edition=fundamental","pubTime":"2026-10-02 09:36","pubTimestamp":1790905004,"startTime":"0","endTime":"0","summary":"On October 2, INNOVENT BIO fell 3.47% in regular trading, trading at HK$92.9/share, with turnover of HK$90.83 million.Within the Biotechnology sector where INNOVENT BIO belongs, the overall sector...","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01801"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2672735924","title":"What IBI3003 Trial Progress Means For Innovent Biologics Stock","url":"https://stock-news.laohu8.com/highlight/detail?id=2672735924","media":"Simply Wall St.","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2672735924?lang=en_us&edition=fundamental","pubTime":"2026-10-01 07:29","pubTimestamp":1790810983,"startTime":"0","endTime":"0","summary":"Innovent Biologics reported updated Phase 1 results for IBI3003, a trispecific antibody for relapsed or refractory multiple myeloma, with a recommended Phase 2 dose of 360 µg/kg and high response rates in heavily pretreated patients, alongside fresh regulatory progress including China approval of Jaypirca for CLL/SLL.\nThe combination of a broad, clinically active pipeline, EMA GMP certification for the Suzhou manufacturing site, and new China market access for Jaypirca highlights how...","market":"nz","thumbnail":"https://simplywall.st/cdn-cgi/image/fit=cover,format=auto,width=320,height=180/https://images.simplywall.st/asset/industry/6111000-choice1-card/1788937617532","type":0,"news_type":0,"thumbnails":["https://simplywall.st/cdn-cgi/image/fit=cover,format=auto,width=320,height=180/https://images.simplywall.st/asset/industry/6111000-choice1-card/1788937617532"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/hk/pharmaceuticals-biotech/hkg-1801/innovent-biologics-shares/news/what-ibi3003-trial-progress-means-for-innovent-biologics-sto","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/hk/pharmaceuticals-biotech/hkg-1801/innovent-biologics-shares/news/what-ibi3003-trial-progress-means-for-innovent-biologics-sto","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["LU1831875114.USD","LU2097828557.USD","LU2097828714.EUR","BK4097","LU0244354667.USD","LU2097828474.EUR","KURE","LU0607220059.USD","LU0326950275.SGD","LU0149534421.HKD","PRGS","LU0455707207.USD","LU1188198961.HKD","LU2065732104.USD","BK1583","BK1589","LU0502904849.HKD","LU2097828805.USD","LU2488822045.USD","BK1161","LU2328871848.SGD","01801","LU2242644610.SGD","LU1969619763.USD","LU2097828631.EUR","HK0000165453.HKD","LU0463099449.HKD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2671051201","title":"Major Drugmakers Turn to China for Licensing Deals","url":"https://stock-news.laohu8.com/highlight/detail?id=2671051201","media":"Reuters","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2671051201?lang=en_us&edition=fundamental","pubTime":"2026-09-30 20:17","pubTimestamp":1790770671,"startTime":"0","endTime":"0","summary":"FACTBOX-Major drugmakers turn to China for licensing dealsSept 30 (Reuters)-Novo NordiskNOVOb.COsaid on Tuesday it will pay up to$2.6 billionto Jiangsu Hengrui Pharmaceuticals600276.SSfor the rights t","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260930:nL4N45M0T3:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["WDNA","LLYX","GDOC","01801","MRK","TRUH","THNR","MEDI","TMED","AGNG","600276","LLYZ","RXL","OZEM","09926","VHT","FTXH","BMED","KURE","IYH","CGNX","IHE","PFE","HRTS","IXJ","LLY","MEDX","ILDR","00013","PJP","PAWZ","688331","ELIS","CURE","ELIL","RSHO","PPH","BNTX","03692","JDOC","LLII","SMMT","GSK.UK","FHLC","GLAM","XLV","01530","CANC","ABBV","MHIP"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1150331675","title":"Movement Alert｜INNOVENT BIO Rises 3.18% in Regular Trading, Strong Interim Results and New Drug Approval Boost Sentiment","url":"https://stock-news.laohu8.com/highlight/detail?id=1150331675","media":"Market Focus","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1150331675?lang=en_us&edition=fundamental","pubTime":"2026-09-30 10:39","pubTimestamp":1790735980,"startTime":"0","endTime":"0","summary":"On September 30, INNOVENT BIO rose 3.18% in regular trading, trading at 98.85 HKD/share, with turnover of HKD 534 million.The rally was driven by a combination of robust interim financial results and...","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"Innovent Bio Gains as Nomura and Jefferies Lift Targets","news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01801"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2671914282","title":"Innovent Says Trispecific Antibody Ibi3003 Posts 84.6% ORR at Phase 1 RP2D in Relapsed/refractory Multiple Myeloma","url":"https://stock-news.laohu8.com/highlight/detail?id=2671914282","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2671914282?lang=en_us&edition=fundamental","pubTime":"2026-09-29 15:46","pubTimestamp":1790667978,"startTime":"0","endTime":"0","summary":"Innovent says trispecific antibody IBI3003 posts 84.6% ORR at Phase 1 RP2D in relapsed/refractory multiple myelomaInnovent disclosed updated Phase 1 results for IBI3003 in relapsed or refractory multi","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260929:nNDLTnt3K:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01801","LU1188198961.HKD","KURE","LU2242644610.SGD","LU2097828714.EUR","BK1583","LU0502904849.HKD","01911","BK1147","LU2097828557.USD","LU0326950275.SGD","LU0244354667.USD","BK1589","LU2097828474.EUR","LU2097828805.USD","LU0607220059.USD","LU2328871848.SGD","HK0000165453.HKD","LU0455707207.USD","LU0463099449.HKD","LU2488822045.USD","BK1161","LU0149534421.HKD","LU1969619763.USD","LU2097828631.EUR","LU1831875114.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2671291456","title":"2026 Ims Oral Presentation: Innovent Announces Updated Phase 1 Clinical Data of Trispecific Antibody Ibi3003 (Gprc5d/Bcma/Cd3) in Patients with Relapsed or Refractory Multiple Myeloma","url":"https://stock-news.laohu8.com/highlight/detail?id=2671291456","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2671291456?lang=en_us&edition=fundamental","pubTime":"2026-09-29 15:45","pubTimestamp":1790667949,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260929:nTUA3L9QVD:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["LU0463099449.HKD","KURE","LU2097828557.USD","LU2242644610.SGD","LU1969619763.USD","LU2328871848.SGD","LU2097828631.EUR","LU0149534421.HKD","LU2097828474.EUR","BK1583","HK0000165453.HKD","LU2488822045.USD","LU1188198961.HKD","LU0244354667.USD","LU0455707207.USD","01801","LU0607220059.USD","BK1589","LU0326950275.SGD","BK1161","LU2097828714.EUR","LU2097828805.USD","LU1831875114.USD","LU0502904849.HKD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2670255552","title":"US Drugmakers Turn to China for Licensing Deals","url":"https://stock-news.laohu8.com/highlight/detail?id=2670255552","media":"Reuters","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2670255552?lang=en_us&edition=fundamental","pubTime":"2026-09-28 22:31","pubTimestamp":1790605880,"startTime":"0","endTime":"0","summary":"FACTBOX-US drugmakers turn to China for licensing dealsSept 28 (Reuters)-MerckMRK.Non Monday agreed to payChinese biotechSciBrunch Therapeutics $400 million upfront for global rights to an experimenta","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260928:nL4N45K0UD:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2237443549.SGD","LU1883839398.USD","LU2168564065.EUR","IE000MB6IJN5.SGD","LU0912757837.SGD","SG9999014898.SGD","LU2491050071.SGD","LU0456855351.SGD","LU0683600562.USD","SG9999014906.USD","IE0009355771.USD","MEDI","IE00B19Z3581.USD","IE00B3T34201.USD","LU2168564495.EUR","LU0965509101.SGD","SG9999011175.SGD","BMED","IE000WAW04H5.SGD","LU2133065610.SGD","LU0859254822.USD","IE0004445015.USD","LU0094547139.USD","LU2456880835.USD","LU1691799644.USD","LU2112291526.USD","LU0306806265.USD","LU2491049909.HKD","LU0385154629.USD","LU0345770308.USD","LU1548497426.USD","LU0511384066.AUD","LU1670710588.SGD","LU1629891620.HKD","IE00B1XK9C88.USD","CURE","ELIS","LU0553294199.USD","LU1551013425.SGD","LU0109391861.USD","LU1571399168.USD","IE00BFTCPJ56.SGD","LU1244550221.USD","REGN","TMED","LU0417517546.SGD","LU1804176565.USD","LU0726765562.USD","LU0210536198.USD","LU2357627491.SGD","LU0868494617.USD","LU0170899867.USD","ELIL","LU2756315664.SGD","LU0889565916.HKD","BK4533","LU0882574139.USD","IE00BFSS8Q28.SGD","IE00BBT3K403.USD","LU0672654240.SGD","LU0130517989.USD","LU1934455863.HKD","LU2097828631.EUR","IE00BKDWB100.SGD","LU0267386448.USD","LU0072461881.USD","LU0158827948.USD","LU2328871848.SGD","LU2168564222.USD","LU0943347566.SGD","SG9999015952.SGD","SG9999014880.SGD","AGNG","LU2468319806.SGD","LU1814569148.SGD","RXL","LU2028103732.USD","LU0225771236.USD","LU0648001328.SGD","LU2063271972.USD","SG9999014914.USD","LU2097828805.USD","LU2023250843.SGD","LU0321505439.SGD","LU1868837136.USD","BK4585","LU0256863902.USD","LU0289739343.SGD","BK4532","LU1236620750.USD","LU0321505868.SGD","LU0985320562.USD","SG9999015945.SGD","LU0098860793.USD","LU0058720904.USD","LU0211331839.USD","LU0265550946.USD","LU1720051108.HKD","LU1934455194.USD","LU2125909593.SGD","LU2360032135.SGD","LU0471298694.HKD","LU2746668974.SGD","LU0289961442.SGD","IE00BVYPNV92.GBP","LU1670710661.SGD","LU0965509010.AUD","LU1037948897.HKD","LU1917777945.USD","LU1066051811.HKD","LU0432979614.USD","LU0985481810.HKD","JDOC","LU2089284900.SGD","BK4007","SGXZ51526630.SGD","LU0203201768.USD","LU2271345857.HKD","LU2471134879.HKD","LU0738911758.USD","LU2097828474.EUR","LU1035775433.USD","IE00BSNM7G36.USD","LU0244354667.USD","LU2746668461.USD","LU2211815571.USD","LU1989772923.USD","LU2596442595.SGD","TBXU","BK1589","LU1074936037.SGD","LU0466842654.USD","LU2361045086.USD","LU1983299246.USD","BK4592","LU0106261372.USD","LU0225283273.USD","LU1868836757.USD","IE00BLSP4452.SGD","ABBV","LU1188198961.HKD","LU2471134523.USD","LU0320765992.SGD","LU0061475181.USD","LU1923622614.USD","IE00BJJMRY28.SGD","LLYZ","LU2417539215.USD","LU2552382215.SGD","LU1585245621.USD","IE00BN29S564.USD","XLV","LU1969619763.USD","MRK","LU2168563687.JPY","LU0203202063.USD","LU1201861249.SGD","LU0162691827.USD","SG9999001440.SGD","MEDX","LU0708994859.HKD","LU0097036916.USD","GLAM","IE0002270589.USD","LU2237443895.HKD","LU2462591350.SGD","LU2360106947.USD","LU1732799900.SGD","LU0256863811.USD","LU2125154778.USD","LU2357305700.SGD","LU1232071149.USD","BK4599","LU0149534421.HKD","LU1116320901.HKD","LU2089283258.USD","LU1267930573.SGD","LU2023250504.SGD","LU2237443622.USD","LU0208291251.USD","LU0640476718.USD","LU2750360641.GBP","LU2488822045.USD","LU0320765646.SGD","LU1732800096.USD","IE0000B7K699.USD","SGXZ99366536.SGD","OZEM","LU2756315318.SGD","LU1069347547.HKD","IE00B2B36J28.USD","LU1430594728.SGD","LU0234570918.USD","ILDR","LU1941712264.USD","IXJ","LU2168564149.EUR","LU2324357040.USD","BBH","PAWZ","SG9999017495.SGD","LU0787776722.HKD","LU1066051498.USD","LU0477156953.USD","LU1720051017.SGD","SG9999014567.USD","LU0708995401.HKD","LU2125154935.USD","LU0174119429.USD","IE00BJJMRZ35.SGD","FTXH","SG9999001176.USD","LU0964807845.USD","LU2237443382.USD","LLYX","IBB","IE00BK4W5L77.USD","SG9999013999.USD","IE00BFSS7M15.SGD","LU0211327993.USD","LU2264538146.SGD","LU2552382058.USD","GDOC","LU0354030511.USD","LU2213496289.HKD","LU0053666078.USD","LU0211328371.USD","LU1244550494.USD","LU0310799852.SGD","IE00B1BXHZ80.USD","LU1066053197.SGD","BMY","LU1280957306.USD","IBBQ","IE00B7KXQ091.USD","IE00B42XCP33.USD","LU0795875169.SGD","LU1934455277.USD","IE00BK4W5M84.HKD","LU2236285917.USD","BK4550","LU0689472784.USD","IE00B3PB1722.GBP","LU0395794307.EUR","SG9999003800.SGD","LU0320765489.SGD","IE000F7OJYX1.SGD","KURE","LU1267930730.SGD","LU1974910355.USD","LU0868494708.USD","LU0326950275.SGD","LU2491050154.USD","LU0158827781.USD","LU2461242641.AUD","IE00BLSP4239.USD","LU1894683264.USD","IE000SO60NU8.SGD","LU2023251221.USD","IYH","LU2097828557.USD","BK4534","LU0070302665.USD","LU0861579265.USD","LU0310800379.SGD","LU2111349929.HKD","LU1064131342.USD","LU0122379950.USD","PPH","SG9999014542.SGD","LU0965508806.USD","LU2237443978.SGD","LU2129689514.USD","LU2125909247.SGD","BK4559","LU1267930490.SGD","IHE","LU0820562030.AUD","LU1023059063.AUD","LU1941712348.USD","01801","LU0471298777.SGD","LU0006306889.USD","LU0079474960.USD","LU1061106388.HKD","BK1583","IE00BJT1NW94.SGD","IE000BZT7R73.USD","LU0265550359.USD","LU1057294990.SGD","LU2362541513.USD","LU1551013342.USD","IE00B4JS1V06.HKD","LU2242652126.USD","LU1032466523.USD","SG9999014559.SGD","LU0354030438.USD","LU0661504455.SGD","IE00B4R5TH58.HKD","LU2471134796.USD","LU1868837300.USD","LU1623119135.USD","LU0198837287.USD","BK4588","IE0005OL40V9.USD","LU1868836914.USD","LU1093756168.USD","LU0057025933.USD","LU2237438978.USD","IE00BDGV0183.EUR","SG9999014575.USD","LU1291159041.SGD","LU2361044865.SGD","LU0225284248.USD","LU0237698245.USD","LU2347655156.SGD","LU0823416689.USD","LU1989772840.SGD","IE00BKPKM429.USD","LU0128525929.USD","LU2602419157.SGD","LU1496350502.SGD","LU0069063385.USD","LU2433249047.HKD","LU1670628061.USD","LU0689626769.HKD","SG9999015341.SGD","IE00BJLML261.HKD","LU0109394709.USD","LU0949170772.SGD","LU1093756325.SGD","LU1988902786.USD","LU0502904849.HKD","SG9999018857.SGD","LU2089984988.USD","IE00BN8TJ469.HKD","SG9999002224.SGD","SG9999015358.SGD","LU0234572021.USD","BK1161","LU2097828714.EUR","LU0323591593.USD","LU2750360997.AUD","LU0114720955.EUR","LU0942090050.USD","IE00BJJMRX11.SGD","LU2023250330.USD","BK4139","LU2242644610.SGD","LU2237443465.HKD","LU2362541273.HKD","LU1670627923.USD","IE00B19Z3B42.SGD","SG9999002232.USD","BK4581","GB00BDT5M118.USD","LU0320765059.SGD","LU2471134952.CNY","LU2108987350.USD","LU0096364046.USD","LU1699723380.USD","LU1037948541.HKD","LU0130102774.USD","LU0820561909.HKD","LU2087625088.SGD","LU1670711040.USD","BK4516","LU1261432733.SGD","LU1366192091.USD","LU2362540622.SGD","SG9999018865.SGD","BK4566","LU0795875086.SGD","LU1236620834.HKD","LU0316494557.USD","LU0545039389.USD","LU1069344957.HKD","LU1831875114.USD","IE0001KFT4U8.USD","LU0266013472.USD","LU2265009873.SGD","LU0455707207.USD","IE00BFXG1179.USD","LU0353189680.USD","IE000M9KFDE8.USD","LU1712237335.SGD","PJP","LU0133085943.USD","LU2462157665.USD","VHT","LU0472753341.HKD","LU1839511570.USD","LU1244550577.SGD","IE00BWXC8680.SGD","LU0124676726.USD","LU0238689110.USD","IE00BGHQF631.EUR","LU2896262040.SGD","LU0345770993.USD","THNR","LU0289739699.SGD","CANC","LU0823434740.USD","LLY","LU1127390331.HKD","LU2129689431.USD","LU1894683348.USD","BK4568","LU1035773651.USD","IE0004445239.USD","LU1670711123.USD","LU0820561818.USD","FHLC","LU0965509283.SGD","LU1979441026.SGD","SGXZ31699556.SGD","LLII","WDNA","LU0882574055.USD","LU0353189763.USD","LU0029864427.USD","LU1496350171.SGD","HRTS","LU0203347892.USD","LU0306807586.USD","LU2129689605.HKD","LU0980610538.SGD","LU2087621335.USD","LU2552382132.HKD","IE0002141913.USD","LU1989771016.USD","SGXZ57979304.SGD","LU1162221912.USD","LU1868836591.USD","LU2242646821.SGD","LU1718418525.SGD","HK0000165453.HKD","TRUH","IE00BVYPNW00.USD","LU1066051225.USD","LU2106854487.HKD","SG9999015986.USD","LU0463099449.HKD","LU0607220059.USD","SG9999015978.USD","LU1003077747.HKD","LU1323610961.USD","LU0203345920.USD","MHIP","SG9999001176.SGD","LU0786609619.USD","LU2347655073.USD","LU0823434583.USD","LU2361044949.HKD","IE00B775H168.HKD","LU1116320737.USD","LU1929549753.HKD","SGXZ81514606.USD","LU1145028129.USD","PFE"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2670625231","title":"Innovent Biologics Gets China Nod for Jaypirca to Treat Chronic Lymphocytic Leukemia","url":"https://stock-news.laohu8.com/highlight/detail?id=2670625231","media":"MT Newswires Live","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2670625231?lang=en_us&edition=fundamental","pubTime":"2026-09-28 19:15","pubTimestamp":1790594155,"startTime":"0","endTime":"0","summary":"Innovent Biologics (HKG:1801) obtained approval for Jaypirca from China's National Medical Products Administration, a Monday bourse filing showed.The approval is for the drug as monotherapy to treat adult patients with chronic lymphocytic leukemia/small lymphocytic lymphoma.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["LU2488822045.USD","LU2328871848.SGD","LU1831875114.USD","LU1969619763.USD","LU2097828557.USD","HK0000165453.HKD","BK1583","LU0607220059.USD","BK1161","LU0149534421.HKD","LU0463099449.HKD","LU1188198961.HKD","BK1589","LU0455707207.USD","LU0502904849.HKD","LU2097828474.EUR","LU2097828714.EUR","LU2097828631.EUR","01801","KURE","LU0326950275.SGD","LU0244354667.USD","LU2242644610.SGD","LU2097828805.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2670239864","title":"Jaypirca® (Pirtobrutinib) Approved in China for a New Indication in Chronic Lymphocytic Leukemia (Cll) /Small Lymphocytic Lymphoma (Sll) Across All Lines of Therapy","url":"https://stock-news.laohu8.com/highlight/detail?id=2670239864","media":"Reuters","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2670239864?lang=en_us&edition=fundamental","pubTime":"2026-09-28 18:39","pubTimestamp":1790591992,"startTime":"0","endTime":"0","summary":"BRIEF-Jaypirca (Pirtobrutinib) Approved In China For A New Indication In Chronic Lymphocytic Leukemia (Cll) /Small Lymphocytic Lymphoma (Sll) Across All Lines Of TherapySept 28 (Reuters)-Innovent Biol","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260928:nTUA2WRDHQ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1161","LU2097828714.EUR","LU2328871848.SGD","LU0455707207.USD","LU0326950275.SGD","BK1583","HK0000165453.HKD","LU2242644610.SGD","LU2097828557.USD","LU2097828474.EUR","LU1188198961.HKD","LU0463099449.HKD","LU0149534421.HKD","LU0244354667.USD","LU0607220059.USD","LU2097828805.USD","LU0502904849.HKD","LU1969619763.USD","LU2488822045.USD","KURE","LU2097828631.EUR","LU1831875114.USD","01801","BK1589"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1174068672","title":"Innovent's Jaypirca (pirtobrutinib) wins NMPA approval for all-line CLL/SLL treatment in China","url":"https://stock-news.laohu8.com/highlight/detail?id=1174068672","media":"Stock News","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1174068672?lang=en_us&edition=fundamental","pubTime":"2026-09-28 18:18","pubTimestamp":1790590702,"startTime":"0","endTime":"0","summary":"Innovent Biologics (01801) has announced that its marketed non-covalent (reversible) Bruton's tyrosine kinase (BTK) inhibitor Jaypirca (pirtobrutinib) has officially received approval from China's...","market":"sg","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0149534421.HKD","LU0326950275.SGD","HK0000165453.HKD","BK1583","BK1161","LU1969619763.USD","01801","LU2097828557.USD","LU2097828805.USD","KURE","LU2488822045.USD","LU0455707207.USD","LU2242644610.SGD","LU0244354667.USD","LU2097828631.EUR","LU2328871848.SGD","LU0607220059.USD","LU1831875114.USD","LU0463099449.HKD","LU2097828474.EUR","LU0502904849.HKD","LU1188198961.HKD","BK1589","LU2097828714.EUR"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2670236395","title":"Innovent Biologics - Jaypirca (Pirtrobrutinib) Approved in China for Cll/Sll Across All Lines of Therapy","url":"https://stock-news.laohu8.com/highlight/detail?id=2670236395","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2670236395?lang=en_us&edition=fundamental","pubTime":"2026-09-28 18:11","pubTimestamp":1790590260,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260928:nFWN45I0DL:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["LU0455707207.USD","BK1161","BK1583","LU2097828474.EUR","LU2097828714.EUR","KURE","LU1188198961.HKD","LU1969619763.USD","LU2097828557.USD","LU0607220059.USD","LU0149534421.HKD","LU0463099449.HKD","LU2097828805.USD","LU1831875114.USD","01801","BK1589","LU2242644610.SGD","LU2097828631.EUR","LU0502904849.HKD","LU2328871848.SGD","LU2488822045.USD","LU0326950275.SGD","LU0244354667.USD","HK0000165453.HKD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1124757372","title":"Movement Alert｜INNOVENT BIO Falls 3.31% in Regular Trading, Trading at 96.35 HKD","url":"https://stock-news.laohu8.com/highlight/detail?id=1124757372","media":"Market Focus","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1124757372?lang=en_us&edition=fundamental","pubTime":"2026-09-28 10:09","pubTimestamp":1790561367,"startTime":"0","endTime":"0","summary":"On September 28, INNOVENT BIO fell 3.31% in regular trading, trading at 96.35 HKD/share, with Turnover of HKD 156 million.Within the Biotechnology sector where INNOVENT BIO belongs, sector...","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01801"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2670402351","title":"Innovent Expands Phase 3 MarsLight-11 Trial of Ibi363/tak-928 to Include Non-Squamous NSCLC Patients","url":"https://stock-news.laohu8.com/highlight/detail?id=2670402351","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2670402351?lang=en_us&edition=fundamental","pubTime":"2026-09-28 08:00","pubTimestamp":1790553625,"startTime":"0","endTime":"0","summary":"Innovent expands Phase 3 MarsLight-11 trial of IBI363/TAK-928 to include non-squamous NSCLC patientsInnovent Biologics expanded its global Phase 3 MarsLight-11 trial of IBI363/TAK-928 to include non-s","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260928:nNDL8bvkF3:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01801","LU1831875114.USD","LU0607220059.USD","KURE","01911","BK1589","LU1969619763.USD","LU2328871848.SGD","LU1188198961.HKD","LU0326950275.SGD","LU0502904849.HKD","LU2097828631.EUR","LU2097828805.USD","BK1147","LU0455707207.USD","LU2097828714.EUR","LU0463099449.HKD","LU2097828557.USD","LU0149534421.HKD","HK0000165453.HKD","BK1161","LU0244354667.USD","LU2097828474.EUR","LU2488822045.USD","BK1583","LU2242644610.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2670402334","title":"Innovent Announces Expansion of Global Phase 3 Marslight-11 Study of Ibi363/Tak-928 (Alpha-Biased Il-2/Pd-1 Bispecific Fusion Protein) in Immunotherapy-Resistant Nsclc to Include Patients with Non-Squamous Nsclc","url":"https://stock-news.laohu8.com/highlight/detail?id=2670402334","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2670402334?lang=en_us&edition=fundamental","pubTime":"2026-09-28 08:00","pubTimestamp":1790553600,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260928:nTUAQM6DS:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["LU2488822045.USD","LU2097828714.EUR","01801","LU0149534421.HKD","LU0455707207.USD","LU0326950275.SGD","LU1831875114.USD","BK1161","LU0463099449.HKD","KURE","LU1969619763.USD","HK0000165453.HKD","LU2097828805.USD","LU2328871848.SGD","LU1188198961.HKD","LU2097828631.EUR","LU0502904849.HKD","LU2097828557.USD","LU2097828474.EUR","LU2242644610.SGD","LU0244354667.USD","BK1589","LU0607220059.USD","BK1583"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1159232938","title":"Movement Alert｜INNOVENT BIO Falls 3.29% in Regular Trading, Trading at 100.1 HKD","url":"https://stock-news.laohu8.com/highlight/detail?id=1159232938","media":"Market Focus","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1159232938?lang=en_us&edition=fundamental","pubTime":"2026-09-24 10:00","pubTimestamp":1790215221,"startTime":"0","endTime":"0","summary":"On September 24, INNOVENT BIO fell 3.29% in regular trading, trading at 100.1 HKD/share, with turnover of HKD 107 million.Within the Biotechnology sector where INNOVENT BIO belongs, the overall...","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01801"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1100645757","title":"INNOVENT BIO Posts Robust Growth on Dual Momentum From Oncology and Integrated Product Lines","url":"https://stock-news.laohu8.com/highlight/detail?id=1100645757","media":"Deep News","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1100645757?lang=en_us&edition=fundamental","pubTime":"2026-09-23 18:10","pubTimestamp":1790158246,"startTime":"0","endTime":"0","summary":"INNOVENT BIO has delivered another period of strong financial performance, with total revenue for the first half of 2026 reaching RMB 8.618 billion, a year-on-year increase of 44.8%. Product revenue...","market":"other","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["09939","LU2097828557.USD","LU0326950275.SGD","LU0607220059.USD","LU2328871848.SGD","01801","LU1188198961.HKD","BK1589","LU1831875114.USD","LU2097828805.USD","LU2488822045.USD","LU0244354667.USD","LU0463099449.HKD","BK1515","LU0502904849.HKD","LU1969619763.USD","LU2097828714.EUR","LU0455707207.USD","HK0000165453.HKD","BK1583","159938","LU2242644610.SGD","LU0149534421.HKD","LU2097828631.EUR","KURE","LU2097828474.EUR","BK1574","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669092751","title":"Innovent to Present Phase 3 Interim Data for Cldn18.2 ADC Ibi343 in Third-Line Gastric Cancer at ESMO 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2669092751","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2669092751?lang=en_us&edition=fundamental","pubTime":"2026-09-23 16:49","pubTimestamp":1790153370,"startTime":"0","endTime":"0","summary":"Innovent to present phase 3 interim data for CLDN18.2 ADC IBI343 in third-line gastric cancer at ESMO 2026Innovent Biologics scheduled new clinical readouts for its next-generation immuno-oncology and","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260923:nNDLc9g4S:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2097828631.EUR","BK1161","LU1969619763.USD","LU2328871848.SGD","HK0000165453.HKD","LU0244354667.USD","LU2097828557.USD","LU0502904849.HKD","LU2097828474.EUR","LU1831875114.USD","KURE","LU2242644610.SGD","LU1188198961.HKD","BK1583","01911","BK1589","LU0463099449.HKD","LU0149534421.HKD","01801","LU2488822045.USD","LU2097828714.EUR","BK1147","LU0455707207.USD","LU2097828805.USD","LU0607220059.USD","LU0326950275.SGD"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.innoventbio.com","stockEarnings":[{"period":"1week","weight":-0.0056},{"period":"1month","weight":-0.0375},{"period":"3month","weight":0.1291},{"period":"6month","weight":0.1017},{"period":"1year","weight":-0.0299},{"period":"ytd","weight":0.2787}],"compareEarnings":[{"period":"1week","weight":-0.0196},{"period":"1month","weight":-0.0505},{"period":"3month","weight":0.0042},{"period":"6month","weight":-0.0681},{"period":"1year","weight":-0.1049},{"period":"ytd","weight":-0.0585}],"compareStock":{"symbol":"HSI","name":"HSI"},"description":"Innovent Biologics Inc is an investment holding company principally engaged in the research, development, production and sales of innovative medicines for the treatment of diseases such as cancer, cardiovascular and metabolic (CVM), autoimmune and eye diseases. The pipeline covering monoclonal antibodies, multi-specific antibodies, immuno-cytokine, antibody-drug conjugates (ADCs), cell therapy and small molecules. The Company’s main products include TYVYT (sintilimab injection), BYVASDA (bevacizumab injection), SULINNO (adalimumab injection), HALPRYZA (rituximab injection), Pemazyre (pemigatinib) and others. The Company mainly conducts its businesses within domestic and overseas markets.","yearOnYearQuotes":[{"month":1,"riseRate":0.5,"avgChangeRate":-0.041076},{"month":2,"riseRate":0.75,"avgChangeRate":0.110526},{"month":3,"riseRate":0.25,"avgChangeRate":-0.01934},{"month":4,"riseRate":0.75,"avgChangeRate":0.043223},{"month":5,"riseRate":0.375,"avgChangeRate":0.014737},{"month":6,"riseRate":0.625,"avgChangeRate":0.116146},{"month":7,"riseRate":0.5,"avgChangeRate":0.019948},{"month":8,"riseRate":0.75,"avgChangeRate":0.024842},{"month":9,"riseRate":0.5,"avgChangeRate":0.021235},{"month":10,"riseRate":0.25,"avgChangeRate":-0.020703},{"month":11,"riseRate":0.625,"avgChangeRate":0.079172},{"month":12,"riseRate":0.375,"avgChangeRate":0.024026}],"exchange":"SEHK","name":"INNOVENT BIO","nameEN":"INNOVENT BIO"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.50.1","shortVersion":"4.50.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"INNOVENT BIO(01801),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest INNOVENT BIO(01801) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"INNOVENT BIO,01801,INNOVENT BIO股票,INNOVENT BIO股票老虎,INNOVENT BIO股票老虎国际,INNOVENT BIO行情,INNOVENT BIO股票行情,INNOVENT BIO股价,INNOVENT BIO股市,INNOVENT BIO股票价格,INNOVENT BIO股票交易,INNOVENT BIO股票购买,INNOVENT BIO股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"INNOVENT BIO(01801),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest INNOVENT BIO(01801) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}